Hypercalcemia of Malignancy: Simultaneous Elevation in Parathyroid Hormone-Related Peptide and 1,25 Dihydroxyvitamin D in Sarcoma.
Hypercalcemia of Malignancy: Simultaneous Elevation in Parathyroid Hormone-Related Peptide and 1,25 Dihydroxyvitamin D in Sarcoma.
复制标题
DOI：
10.1016/j.aace.2020.11.037
复制
发表时间：
2021-05
影响因子：
--
通讯作者：
Silver KD
中科院分区：
文献类型：
--
作者：
Kim DW;Miller A;Li A;Hardy N;Silver KD
高钙血症是一种常见的发现，在病人谁有潜在的恶性肿瘤。只有少数恶性肿瘤的高钙血症与一种以上的高钙血症机制有关。在此，我们报告一例脂肪肉瘤伴高钙血症的恶性肿瘤患者，其甲状旁腺素相关肽（PTHrP）和1，25二羟维生素D [1，25（OH）2D]水平同时升高。肉瘤相关的高钙血症是一种罕见的疾病。患者是一名89岁的女性，患有肉瘤相关的高钙血症。发现了多种机制，并对其进行了治疗调整。对多种机制的恶性肿瘤高钙血症进行了文献检索。这是第一份描述肉瘤相关高钙血症双重机制的报告，也是第五份关于PTHrP和1，25（OH）2D同时引起恶性肿瘤高钙血症的报告。基于这一发现，我们建议在恶性肿瘤患者中结合PTHrP水平测量1，25（OH）2D水平，因为这将有助于更积极地诊断和治疗恶性肿瘤高钙血症。
Hypercalcemia is a common finding in patients who have an underlying malignancy. Only a few cases of hypercalcemia of malignancy have been linked to more than one mechanism of hypercalcemia. Here, we present a patient with liposarcoma and hypercalcemia of malignancy in the setting of simultaneous elevations in parathyroid hormone-related peptide (PTHrP) and 1,25 dihydroxyvitamin D [1,25(OH)2D] levels. Sarcoma-associated hypercalcemia is a rare disorder. The patient was an 89-year-old woman with sarcoma-associated hypercalcemia. Multiple mechanisms were uncovered, and treatments were adjusted for them. Literature search for hypercalcemia of malignancy with multiple mechanisms was conducted. This is the first report describing dual mechanisms of sarcoma-associated hypercalcemia and only the fifth report on PTHrP and 1,25(OH)2D simultaneously causing hypercalcemia of malignancy. Based on this finding, we recommend measuring the 1,25(OH)2D levels in conjunction with the PTHrP level in patients with malignancy as this would allow for a more proactive approach to the diagnosis and treatment of hypercalcemia of malignancy.